Last reviewed · How we verify

pentoxifylline (drug) — Competitive Intelligence Brief

pentoxifylline (drug) (pentoxifylline (drug)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase inhibitor / Rheological agent. Area: Cardiovascular / Vascular disease.

marketed Phosphodiesterase inhibitor / Rheological agent Phosphodiesterase (non-selective) Cardiovascular / Vascular disease Small molecule Live · refreshed every 30 min

Target snapshot

pentoxifylline (drug) (pentoxifylline (drug)) — National Taiwan University Hospital. Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
pentoxifylline (drug) TARGET pentoxifylline (drug) National Taiwan University Hospital marketed Phosphodiesterase inhibitor / Rheological agent Phosphodiesterase (non-selective)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase inhibitor / Rheological agent class)

  1. National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pentoxifylline (drug) — Competitive Intelligence Brief. https://druglandscape.com/ci/pentoxifylline-drug. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: